Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

Basit Öğe Kaydı
dc.authoridAl-Ghamdi, Mohammed. I./0000-0002-9794-554X
dc.authoridKao, JH/0000-0002-2442-7952
dc.authoridQureshi, Huma/0000-0001-7120-4893
dc.authoridWong, Vincent Wing-Hei/0000-0003-4992-4135
dc.authoridLim, Young-Suk/0000-0002-1544-577X
dc.authoridYuen, Richard Man Fung/0000-0001-7985-7725
dc.authoridWaheed, Yasir/0000-0002-5789-4215
dc.contributor.authorRazavi-Shearer, Devin M.
dc.contributor.authorButi, Maria
dc.contributor.authorTacke, Frank
dc.contributor.authorTerrault, Norah A.
dc.contributor.authorZeuzem, Stefan
dc.contributor.authorAbbas, Zaigham
dc.contributor.authorAghemo, Alessio
dc.date.accessioned2024-08-31T07:49:55Z
dc.date.available2024-08-31T07:49:55Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground & Aims: Hepatitis delta virus (HDV) is a satellite RNA virus that requires the hepatitis B virus (HBV) for assembly and propagation. Individuals infected with HDV progress to advanced liver disease faster than HBV-monoinfected individuals. Recent studies have estimated the global prevalence of anti-HDV antibodies among the HBV-infected population to be 5-15%. This study aimed to better understand HDV prevalence at the population level in 25 countries/territories. Methods: We conducted a literature review to determine the prevalence of anti-HDV and HDV RNA in hepatitis B surface antigen (HBsAg)-positive individuals in 25 countries/territories. Virtual meetings were held with experts from each setting to discuss the findings and collect unpublished data. Data were weighted for patient segments and regional heterogeneity to estimate the prevalence in the HBV-infected population. The findings were then combined with The Polaris Observatory HBV data to estimate the anti-HDV and HDV RNA prevalence in each country/territory at the population level. Results: After adjusting for geographical distribution, disease stage and special populations, the anti-HDV prevalence among the HBsAg+ population changed from the literature estimate in 19 countries. The highest anti-HDV prevalence was 60.1% in Mongolia. Once adjusted for the size of the HBsAg+ population and HDV RNA positivity rate, China had the highest absolute number of HDV RNA+ cases. Conclusions: We found substantially lower HDV prevalence than previously reported, as prior meta-analyses primarily focused on studies conducted in groups/regions that have a higher probability of HBV infection: tertiary care centers, specific risk groups or geographical regions. There is large uncertainty in HDV prevalence estimates. The implementation of reflex testing would improve estimates, while also allowing earlier linkage to care for HDV RNA+ individuals. The logistical and economic burden of reflex testing on the health system would be limited, as only HBsAg+ cases would be screened.en_US
dc.description.sponsorshipGilead Sciences [IN-US-980-6236]; John C Martin Foundation [2019-G024]en_US
dc.description.sponsorshipThis analysis was funded by a research grant from Gilead Sciences (IN-US-980-6236) and made possible by a grant from John C Martin Foundation (2019-G024). The funders had no role in study design, data collection, data analysis, data interpretation, or preparation of the manuscript.en_US
dc.identifier.doi10.1016/j.jhep.2023.10.043
dc.identifier.endpage242en_US
dc.identifier.issn0168-8278
dc.identifier.issn1600-0641
dc.identifier.issue2en_US
dc.identifier.pmid38030035en_US
dc.identifier.startpage232en_US
dc.identifier.urihttps://doi.org/10.1016/j.jhep.2023.10.043
dc.identifier.urihttps://hdl.handle.net/11454/105024
dc.identifier.volume80en_US
dc.identifier.wosWOS:001184424500001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofJournal of Hepatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240831_Uen_US
dc.subjectNutrition Examination Surveyen_US
dc.subjectB-Virusen_US
dc.subjectRisk-Factorsen_US
dc.subjectNational-Healthen_US
dc.subjectDrug-Usersen_US
dc.subjectInfectionen_US
dc.subjectSeroprevalenceen_US
dc.subjectEpidemiologyen_US
dc.subjectAntibodyen_US
dc.titleAdjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territoriesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu